Gapping down
In reaction to disappointing earnings/guidance: BONT -18.4% (lowers FY13 EPS guidance to a loss of ($0.30) - $0.15 vs $0.60 Capital IQ Consensus Est, down from $0.15-0.75), PGEM -17.6%, SODA -17%, LULU -13.3% (warns for Q4: lowers EPS and revenue guidance below consensus; lowers Q4 comp guidance ), QSII -9.3%, ( announces impairments in its hospital solutions division; 'results wil be below analysts' consensus expectations for revenues and earnings per share), ASNA -8.4% (Ascena Retail Group reports Total comparable sales for Nov-Dec of +1% YoY; lowers FY14 EPS guidance), VOLC -5.3%, EXPR -4% (lowers Q4 EPS below consensus; Q4 comps flat to pos low single digits ), VRTX -1%.
M&A related: SNI -2.5% (WSJ reporting DISCA / SNI merger talks over).
Other news: ICPT -19.9% (reports additional detail about FLINT Trial provided by NIDDIK; Bloomberg discusses that ICPT may seek partners on liver drug, according to reports), CNAT -17.1% (announced plans to initiate a placebo-controlled Phase 2b clinical trial in the second half of 2014 evaluating its lead drug candidate emricasan in Post Orthotopic Liver Transplant recipients), GSE -11.5% (continued weakness; GSE Holdings entered into a waiver and seventh amendment to its first lien senior secured credit facility with General Electric Capital Corporation and the other financial institutions party thereto; will pursue a sale of the co), RNA -9.1% (provides 2014 pipeline and financial outlook ), AMRN -5.4% (still checking), DNKN -1.4% ( updates global growth outlook; added 790 net new Dunkin' Donuts and Baskin-Robbins restaurants globally in 2013), BP -1.4% (plans to appeal some 'fictitious' oil spill claims, according to reports), TOT -0.7% (Reuters discusses that Total (TOT) plans to invest in Britain shale gas).
Analyst comments: PAL -4.5% (downgraded to Underperform from Mkt Perform at Raymond James ), BBRY -2.4% (downgraded to Underperform from Perform at Oppenheimer), CREE -2.3% (downgraded to Hold from Buy at Stifel), SYMC -2% ( downgraded to Underweight from Equal-Weight at Morgan Stanley), SCHW -1% (Charles Schwab downgraded to Underperform from Outperform at Credit Agricole), SFLY -0.9% (downgraded to Equal Weight from Overweight at Barclays; initiated with a Outperform at RBC Capital Mkts), DUK -0.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley), ABX -0.4% (downgraded to Sell from Hold at Canaccord)
M&A related: SNI -2.5% (WSJ reporting DISCA / SNI merger talks over).
Other news: ICPT -19.9% (reports additional detail about FLINT Trial provided by NIDDIK; Bloomberg discusses that ICPT may seek partners on liver drug, according to reports), CNAT -17.1% (announced plans to initiate a placebo-controlled Phase 2b clinical trial in the second half of 2014 evaluating its lead drug candidate emricasan in Post Orthotopic Liver Transplant recipients), GSE -11.5% (continued weakness; GSE Holdings entered into a waiver and seventh amendment to its first lien senior secured credit facility with General Electric Capital Corporation and the other financial institutions party thereto; will pursue a sale of the co), RNA -9.1% (provides 2014 pipeline and financial outlook ), AMRN -5.4% (still checking), DNKN -1.4% ( updates global growth outlook; added 790 net new Dunkin' Donuts and Baskin-Robbins restaurants globally in 2013), BP -1.4% (plans to appeal some 'fictitious' oil spill claims, according to reports), TOT -0.7% (Reuters discusses that Total (TOT) plans to invest in Britain shale gas).
Analyst comments: PAL -4.5% (downgraded to Underperform from Mkt Perform at Raymond James ), BBRY -2.4% (downgraded to Underperform from Perform at Oppenheimer), CREE -2.3% (downgraded to Hold from Buy at Stifel), SYMC -2% ( downgraded to Underweight from Equal-Weight at Morgan Stanley), SCHW -1% (Charles Schwab downgraded to Underperform from Outperform at Credit Agricole), SFLY -0.9% (downgraded to Equal Weight from Overweight at Barclays; initiated with a Outperform at RBC Capital Mkts), DUK -0.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley), ABX -0.4% (downgraded to Sell from Hold at Canaccord)